Yksityiskohtainen opas tulossa pian
Työskentelemme kattavan oppaan parissa kohteelle COPD Assessment Test (CAT). Palaa pian katsomaan vaiheittaiset selitykset, kaavat, käytännön esimerkit ja asiantuntijavinkit.
The COPD Assessment Test (CAT) is a validated, patient-completed health status questionnaire designed to measure the impact of Chronic Obstructive Pulmonary Disease (COPD) on a patient's life. It was developed by Jones et al. and published in 2009. The CAT contains 8 items, each rated on a semantic differential scale from 0 (best) to 5 (worst), giving a total score ranging from 0 to 40. The 8 domains assessed are: cough frequency, sputum production, chest tightness, breathlessness when going uphill or up one flight of stairs, activity limitation at home, confidence leaving home despite lung condition, sleep quality, and energy levels. Each domain reflects a different aspect of the physical, functional, and psychosocial burden of COPD. The CAT is designed to be simple, quick (completed in approximately 2 minutes), and usable across all educational levels with pictorial response scales. Interpretation: a score below 10 indicates low impact on daily life; 10–20 indicates medium impact; 21–30 indicates high impact; above 30 indicates very high impact. The GOLD 2023 guidelines use a CAT threshold of 10 to stratify patients into symptomatic (Group B/D) versus less symptomatic (Group A) COPD categories, which guides the intensity of pharmacotherapy and pulmonary rehabilitation referral. The CAT correlates strongly with the St George's Respiratory Questionnaire (SGRQ), the 6-minute walk test, exacerbation frequency, hospitalisation rates, and mortality in COPD. A clinically meaningful difference is a change of ≥2 points over time. The CAT is recommended over the mMRC Dyspnoea Scale in the GOLD strategy for its broader multidimensional assessment of COPD burden.
CAT Total Score = Sum of 8 items (each 0–5); Range 0–40. This formula calculates cat score by relating the input variables through their mathematical relationship. Each component represents a measurable quantity that can be independently verified.
- 1Patient answers 8 questions using a 6-point semantic differential scale (0 = best, 5 = worst).
- 2Item 1: Cough — 'I never cough' (0) to 'I cough all the time' (5).
- 3Item 2: Phlegm — 'I have no phlegm in my chest at all' (0) to 'My chest is completely full of phlegm' (5).
- 4Item 3: Chest tightness — 'My chest does not feel tight at all' (0) to 'My chest feels very tight' (5).
- 5Item 4: Breathlessness — 'When I walk up a hill or one flight of stairs I am not breathless' (0) to 'very breathless' (5).
- 6Items 5–8 similarly assess: activity at home, confidence leaving home, sleep quality, and energy.
- 7Sum all 8 items; classify: <10 low impact; 10–20 medium; 21–30 high; >30 very high impact on health status.
CAT <10 = GOLD Group A regardless of spirometry severity
A CAT of 7 indicates minimal COPD impact. Treatment is focused on symptom relief as needed and preventive measures.
GOLD 2023 combines previous Groups B and C into one Group B category
Medium CAT score with low exacerbation history places patient in GOLD Group B, where long-acting bronchodilator therapy is the first-line recommendation.
GOLD 2023 uses Group E (formerly D) for frequent exacerbators (≥2 moderate or ≥1 hospitalised exacerbation)
High CAT with frequent exacerbations defines Group E — the highest risk COPD group requiring maximal bronchodilator therapy and often inhaled corticosteroids.
Failure to recover to pre-exacerbation CAT (<10 above baseline) is associated with increased re-hospitalisation risk
Serial CAT measurement tracks exacerbation recovery. A decline from 28 to 18 is substantial improvement, though the patient remains in the medium-high impact range.
Classifying COPD patients into GOLD Groups A/B/E to guide the intensity of pharmacotherapy initiation.. This application is commonly used by professionals who need precise quantitative analysis to support decision-making, budgeting, and strategic planning in their respective fields
Monitoring treatment response to new bronchodilator initiation, smoking cessation, or pulmonary rehabilitation.. Industry practitioners rely on this calculation to benchmark performance, compare alternatives, and ensure compliance with established standards and regulatory requirements
Pre- and post-pulmonary rehabilitation assessment to document patient-centred outcomes.. Academic researchers and students use this computation to validate theoretical models, complete coursework assignments, and develop deeper understanding of the underlying mathematical principles
Tracking exacerbation recovery and identifying patients at high risk of re-hospitalisation.. Financial analysts and planners incorporate this calculation into their workflow to produce accurate forecasts, evaluate risk scenarios, and present data-driven recommendations to stakeholders
Population health management: identifying COPD patients with disproportionately high CAT for their spirometry severity, prompting comorbidity screening.. This application is commonly used by professionals who need precise quantitative analysis to support decision-making, budgeting, and strategic planning in their respective fields
CAT in COPD Exacerbation
The CAT score worsens significantly during exacerbations (average increase of 7–8 points). Serial CAT measurements during and after exacerbation hospital admission can track recovery. Patients who have not returned within 5 points of their pre-exacerbation baseline CAT by 8 weeks post-discharge are at high risk for re-hospitalisation within 90 days and should be considered for early intensive rehabilitation.
CAT in Pulmonary Rehabilitation Assessment
CAT is used as a primary patient-reported outcome measure in pulmonary rehabilitation programmes. An improvement of ≥2 points post-PR represents a successful patient-centred outcome. National PR programmes in the UK (NHS England) require pre- and post-PR CAT measurement for quality assurance and audit purposes.
CAT in COPD with Comorbidities
COPD commonly coexists with depression, anxiety, heart failure, and musculoskeletal pain — all of which worsen CAT scores. In patients with disproportionately high CAT for spirometry severity, screen for depression (PHQ-9) and anxiety (GAD-7), as psychosocial factors may be major drivers of the health status impairment. Treating comorbid depression can improve CAT significantly.
CAT vs SGRQ
The St George's Respiratory Questionnaire (SGRQ) is a 50-item comprehensive COPD health status measure with three domains (symptoms, activity, impacts). It is the research gold standard but takes 15–20 minutes to complete, making it impractical for routine clinical use. CAT was specifically designed as a brief, clinically applicable substitute that strongly correlates with SGRQ (r = 0.80–0.87).
| CAT Score | Impact | GOLD Group | Management Approach |
|---|---|---|---|
| 0–9 | Low | A | SABA as needed; preventive care; smoking cessation |
| 10–20 | Medium | B | Long-acting bronchodilator (LAMA or LABA); pulmonary rehabilitation referral |
| 21–30 | High | B or E | Dual bronchodilator (LAMA+LABA); consider ICS if eos ≥300; PR |
| >30 | Very High | E | Triple therapy (LAMA+LABA+ICS); palliative input; urgent PR |
What is the difference between CAT and mMRC dyspnoea scale?
The mMRC (modified Medical Research Council) dyspnoea scale is a single-item 5-grade scale that only measures breathlessness. It is quick but misses the multidimensional burden of COPD (cough, sputum, energy, sleep, psychological impact). The CAT assesses 8 domains and therefore provides a more comprehensive picture of COPD impact. GOLD guidelines recommend CAT over mMRC for routine assessment, though mMRC remains widely used due to its simplicity. Both use a threshold of CAT ≥10 or mMRC ≥2 to classify patients as symptomatic.
Can CAT be used to diagnose COPD?
No — CAT is a health status questionnaire that measures the impact of COPD, not a diagnostic tool. Diagnosis of COPD requires post-bronchodilator spirometry showing FEV1/FVC <0.70. CAT assesses symptom burden once COPD is established and guides the intensity of treatment, not whether the condition exists. This is an important consideration when working with cat score calculations in practical applications.
What is a clinically meaningful change in CAT score?
A change of 2 or more points on the CAT is considered the minimum clinically important difference (MCID). Following bronchodilator treatment initiation or pulmonary rehabilitation, an improvement of 2+ points suggests meaningful benefit. In exacerbation recovery, failure to return within 5 points of the pre-exacerbation CAT at 8 weeks is associated with worse long-term outcomes.
How does GOLD 2023 use the CAT in classification?
GOLD 2023 classifies COPD into Groups A, B, and E based on two factors: symptom burden (CAT ≥10 or mMRC ≥2 = more symptoms) and exacerbation history. Group A: few symptoms, ≤1 moderate exacerbation (not hospitalised). Group B: more symptoms OR ≤1 moderate exacerbation (not hospitalised). Group E: ≥2 moderate exacerbations or ≥1 hospitalised exacerbation — regardless of symptom burden.
Is the CAT validated across languages and cultures?
Yes — the CAT has been translated and linguistically validated in over 60 languages. It demonstrates consistent psychometric properties across different cultural and linguistic settings. Each translation undergoes forward-backward translation and cognitive debriefing to ensure conceptual equivalence. This is an important consideration when working with cat score calculations in practical applications. The answer depends on the specific input values and the context in which the calculation is being applied.
Can CAT predict exacerbations?
Higher baseline CAT scores are associated with greater exacerbation frequency and severity. A CAT score above 20 is associated with approximately twice the annual exacerbation rate compared to a score below 10. However, CAT is not designed as an exacerbation prediction tool — it captures current health status. The best predictor of future exacerbations remains the history of past exacerbations.
How should the CAT be administered in clinical practice?
The CAT should be self-administered by the patient in the waiting room or clinic, without physician coaching on answers. It should be repeated at each clinic visit (every 3–6 months in stable COPD, and at each exacerbation visit) to track trends. CAT scores should be recorded in the medical record alongside spirometry values and exacerbation history.
Does pulmonary rehabilitation improve CAT scores?
Yes — randomised controlled trials consistently show that pulmonary rehabilitation improves CAT scores by 3–5 points, well above the 2-point MCID. Improvement in CAT reflects gains in exercise tolerance, dyspnoea, anxiety, and social participation. However, benefits are not maintained without continued exercise — relapse in CAT scores occurs within 12 months if rehabilitation is not continued.
Ammattilaisen vinkki
Use the CAT at every clinic visit and during each exacerbation review. A rising CAT trend over 6–12 months in a patient who appears stable on spirometry is a sensitive early warning sign of loss of COPD control, prompting medication review, inhaler technique check, and pulmonary rehabilitation referral.
Tiesitkö?
The COPD Assessment Test was designed specifically to be validated and useable across all literacy levels and cultures. Its distinctive feature — the semantic differential scale with opposing descriptors at each end — was chosen because it does not require reading ability: the pictorial scale with smiling/sad faces can be used by patients who cannot read the words, making it one of the most accessible validated questionnaires in respiratory medicine.